Zhiyun Gong, Jing Yan, Yi Zhang, Yan Chen, Aoshuang Li, Xiaorong Yang, Weizhong Shi, Lin Guo, Tiantian Dai, Feng Dong, Renquan Lu
{"title":"一种新型循环肿瘤细胞富集装置在乳腺癌诊断和监测中的应用。","authors":"Zhiyun Gong, Jing Yan, Yi Zhang, Yan Chen, Aoshuang Li, Xiaorong Yang, Weizhong Shi, Lin Guo, Tiantian Dai, Feng Dong, Renquan Lu","doi":"10.1080/17520363.2025.2521255","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Circulating tumor cells (CTCs) are a critical biomarker for cancer evaluation. The more excellent detection system for CTCs is in demand.</p><p><strong>Patients & methods: </strong>One hundred and thirty-seven breast cancer patients, 97 patients with benign breast diseases, and 42 healthy volunteers were enrolled. Four milliliters of peripheral blood was used for CTCs detection. The performance was assessed by the receiver operator characteristic curve. A short-term follow-up with 23 patients was presented for real-time monitoring.</p><p><strong>Results: </strong>In clinical, CTCs were found in 96.35% of patients with malignant breast cancer and 25.77% of patients with benign breast diseases but not in healthy group, by CytoBot® 2000. The sensitivity and specificity of 89.8% and 98.6%, respectively, when the cutoff value of 1.5 CTCs per 4 ml whole blood. Significant differences of CTC count were found between malignant and nonmalignant group (<i>p</i> < 0.0001), tumor progression (<i>p</i> < 0.0001), and tumor size (<i>p</i> < 0.0001). In follow-up, 82.61% of patients exhibited a reduction in CTC count, which corresponds with medical observation that benefits from treatment. Additionally, CD45<sup>+</sup> positive CTC showed with anomalous pattern during treatment.</p><p><strong>Conclusion: </strong>CTCs and this platform both have practical implications in clinical breast cancer diagnosis and monitoring.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"539-550"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233826/pdf/","citationCount":"0","resultStr":"{\"title\":\"Diagnosis and monitoring of breast cancer with a novel circulating tumor cells enrichment device.\",\"authors\":\"Zhiyun Gong, Jing Yan, Yi Zhang, Yan Chen, Aoshuang Li, Xiaorong Yang, Weizhong Shi, Lin Guo, Tiantian Dai, Feng Dong, Renquan Lu\",\"doi\":\"10.1080/17520363.2025.2521255\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>Circulating tumor cells (CTCs) are a critical biomarker for cancer evaluation. The more excellent detection system for CTCs is in demand.</p><p><strong>Patients & methods: </strong>One hundred and thirty-seven breast cancer patients, 97 patients with benign breast diseases, and 42 healthy volunteers were enrolled. Four milliliters of peripheral blood was used for CTCs detection. The performance was assessed by the receiver operator characteristic curve. A short-term follow-up with 23 patients was presented for real-time monitoring.</p><p><strong>Results: </strong>In clinical, CTCs were found in 96.35% of patients with malignant breast cancer and 25.77% of patients with benign breast diseases but not in healthy group, by CytoBot® 2000. The sensitivity and specificity of 89.8% and 98.6%, respectively, when the cutoff value of 1.5 CTCs per 4 ml whole blood. Significant differences of CTC count were found between malignant and nonmalignant group (<i>p</i> < 0.0001), tumor progression (<i>p</i> < 0.0001), and tumor size (<i>p</i> < 0.0001). In follow-up, 82.61% of patients exhibited a reduction in CTC count, which corresponds with medical observation that benefits from treatment. Additionally, CD45<sup>+</sup> positive CTC showed with anomalous pattern during treatment.</p><p><strong>Conclusion: </strong>CTCs and this platform both have practical implications in clinical breast cancer diagnosis and monitoring.</p>\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"539-550\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233826/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2521255\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2521255","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
目的：循环肿瘤细胞（CTCs）是评估肿瘤的重要生物标志物。需要更优秀的CTCs检测系统。患者与方法：纳入137例乳腺癌患者、97例乳腺良性疾病患者和42例健康志愿者。4毫升外周血用于ctc检测。通过接收机操作者特征曲线对其性能进行评价。对23例患者进行短期随访，进行实时监测。结果：在临床中，96.35%的恶性乳腺癌患者和25.77%的乳腺良性疾病患者发现ctc，但在健康组中未发现ctc。当截断值为每4 ml全血1.5个ctc时，灵敏度和特异性分别为89.8%和98.6%。恶性组与非恶性组CTC计数差异有统计学意义(p p p + CTC在治疗期间呈异常模式。结论：CTCs和该平台在临床乳腺癌诊断和监测中均具有实际意义。
Diagnosis and monitoring of breast cancer with a novel circulating tumor cells enrichment device.
Aims: Circulating tumor cells (CTCs) are a critical biomarker for cancer evaluation. The more excellent detection system for CTCs is in demand.
Patients & methods: One hundred and thirty-seven breast cancer patients, 97 patients with benign breast diseases, and 42 healthy volunteers were enrolled. Four milliliters of peripheral blood was used for CTCs detection. The performance was assessed by the receiver operator characteristic curve. A short-term follow-up with 23 patients was presented for real-time monitoring.
Results: In clinical, CTCs were found in 96.35% of patients with malignant breast cancer and 25.77% of patients with benign breast diseases but not in healthy group, by CytoBot® 2000. The sensitivity and specificity of 89.8% and 98.6%, respectively, when the cutoff value of 1.5 CTCs per 4 ml whole blood. Significant differences of CTC count were found between malignant and nonmalignant group (p < 0.0001), tumor progression (p < 0.0001), and tumor size (p < 0.0001). In follow-up, 82.61% of patients exhibited a reduction in CTC count, which corresponds with medical observation that benefits from treatment. Additionally, CD45+ positive CTC showed with anomalous pattern during treatment.
Conclusion: CTCs and this platform both have practical implications in clinical breast cancer diagnosis and monitoring.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
